Shield Therapeutics PLC Investor Presentation
March 06 2020 - 1:00AM
RNS Non-Regulatory
TIDMSTX
Shield Therapeutics PLC
06 March 2020
Shield Therapeutics plc
("Shield" or the "Group")
Shield Therapeutics to present at the Hardman & Co. Investor
Forum
London, UK, 6 March 2020: Shield Therapeutics plc (LSE: STX), a
commercial stage, pharmaceutical company with a focus on addressing
iron deficiency with its lead product Feraccru (R) /Accrufer (R)
(ferric maltol), will be presenting at the Hardman & Co.
investor forum, providing an overview of the business and the
progress being made by the Company.
Carl Sterritt, Chief Executive Officer, will present at the
Hardman & Co. investor forum on Tuesday 10 March 2020 at Howard
Kennedy LLP, 1 London Bridge, London, SE1 9BG starting from 5.30pm.
The event brings together high net worth investors and private
investors with an interest in growth stocks. The evening will
comprise of each company presenting for 10 to 15 minutes followed
by an opportunity for Q&A.
No new material information will be disclosed at either event
and t he presentations will be made available on the Company
website shortly after the events here:
https://www.shieldtherapeutics.com/investors/presentations
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Carl Sterritt, Chief Executive
Officer +44 (0)20 7186 8500
Tim Watts, Chief Financial
Officer
Nominated Advisor and J oint
Broker
Peel Hunt LLP
James Steel/Dr Christopher
Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/Matt Radley/Alice
Lane +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7584 391
Paul McManus/Lianne Cawthorne 303
About Shield Therapeutics plc
Shield is a de-risked, commercial stage, specialty
pharmaceutical company delivering innovative pharmaceuticals to
address patients' unmet medical needs. The Company's clear purpose
is to develop products that help patients become people again,
enabling them to enjoy the things that make a difference in their
everyday lives . The Group's lead product, Feraccru (R) / Accrufer
(R) has exclusive IP rights until the mid-2030s and is approved for
the treatment of iron deficiency with or without anaemia in adults
in the European Union, the United States and Switzerland. In Europe
it is marketed as Feraccru (R) with commercialisation led by
Norgine BV and in the USA the product will be marketed as Accrufer
(R) with Shield currently in the process of selecting a
commercialisation partner. Shield also has an exclusive licence
agreement with Beijing Aosaikang Pharmaceutical Co. Ltd for the
development and commercialisation of Feraccru(R)/Accrufer(R) in
China, Hong Kong, Macau and Taiwan.
For more information please visit www.shieldtherapeutics.com
About Feraccru (R) /Accrufer(R)
Feraccru (R) /Accrufer(R) is a novel, stable, non-salt based
oral therapy for adults with iron deficiency with or without
anaemia that has been shown to be an efficacious and well-tolerated
therapy in a range of controlled phase 3 trials, including positive
results from the Phase IIIb AEGIS-H2H study in which Feraccru (R)
/Accrufer(R) demonstrated it was non-inferior in delivering
improvements in haemoglobin levels compared to
intravenously-administered (IV) Ferinject(R)/Injectafer(R) (ferric
carboxymaltose). Feraccru (R) /Accrufer(R) therefore offers a
compelling alternative to IV iron for those patients unable to
tolerate salt-based oral iron therapies and wish to avoid the
complexities of infusion-based iron therapies.
When salt-based oral iron therapies are ingested they can cause
a range of mild-to-severe gastrointestinal tract (GI) adverse
events, including nausea, bloating and constipation through the
release and subsequent reactivity of free iron in the GI tract,
leading to poor tolerability, reduced patient compliance and
ultimately treatment failure. Feraccru (R) /Accrufer(R) is not an
iron salt and, as a result, it does not routinely cause the same
treatment-limiting intolerance issues of salt-based iron therapies,
whilst the iron from the ferric maltol molecule can be readily
absorbed.
Prior to Feraccru (R) /Accrufer(R) , IV iron therapies were the
only realistic alternative treatment option for iron deficient
patients with or without anaemia intolerant of or unwilling to be
treated salt-based oral iron therapies. However, use of such an
invasive, costly, inconvenient and complex to administer treatment
option, which is associated with potentially life-threatening and
spontaneous hypersensitivity reactions, means there remains a clear
unmet medical need for these patients to have access to an
effective therapy that is well tolerated, convenient and does not
require hospital-based administration. Feraccru (R) /Accrufer(R)
meets those requirements.
About Iron Deficiency
The WHO states that iron deficiency is the most common and
widespread nutritional disorder in the world. As well as affecting
a large number of women and children in non-industrialized
countries, it is the only nutrient deficiency which is also
significantly prevalent in virtually all industrialised nations.
There are no current global figures for iron deficiency but, using
anaemia as an indirect indicator, it can be estimated that most
preschool children and pregnant women in non-industrialised
countries, together with at least 30-40% in industrialized
countries, are iron deficient.
Forward-Looking Statements
This press release contains forward-looking statements. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements. These forward-looking statements are based on
management's current expectations and include statements related to
the commercial strategy for Feraccru(R)/ Accrufer(R) These
statements are neither promises nor guarantees, but involve known
and unknown risks and uncertainties, many of which are beyond our
control, that may cause actual results, performance or achievements
to be materially different from management's expectations expressed
or implied by the forward-looking statements, including, but not
limited to, risks associated with, the Group's business and results
of operations, competition and other market factors. The
forward-looking statements made in this press release represent
management's expectations as of the date of this press release, and
except as required by law, the Group disclaims any obligation to
update any forward-looking statements contained in this release,
even if subsequent events cause our views to change.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUVOVRRKUORAR
(END) Dow Jones Newswires
March 06, 2020 02:00 ET (07:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024